What changed in 10x Genomics, Inc.'s latest annual report
In the year ended 31 Dec 2025, 10x Genomics, Inc.'s revenue rose 5.2% to USD 642.82m, from USD 610.78m; total liabilities rose 17.5% to USD 245.04m, from USD 208.50m; total assets rose 13.4% to USD 1.04bn, from USD 918.64m.
Year ended 31 Dec 2025. Source: 10-K filed 13 Feb 2026, read it on SEC EDGAR.
USD 610.78m to USD 642.82m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 610.78m | 642.82m | Up 5.2% |
| Net income | -182.63m | -43.54m | Not comparable |
| Total assets | 918.64m | 1.04bn | Up 13.4% |
| Total liabilities | 208.50m | 245.04m | Up 17.5% |
| Shareholders' equity | 710.13m | 796.33m | Up 12.1% |
Questions people ask
Did 10x Genomics, Inc.'s revenue grow last year?
Revenue grew 5.2%, from USD 610.78m to USD 642.82m in the year ended 31 Dec 2025.
Is 10x Genomics, Inc. profitable?
Not in its latest year: it reported a net loss of USD 43.54m in the year ended 31 Dec 2025. The year before: a net loss of USD 182.63m.
Where do these numbers come from?
From 10x Genomics, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with 10x Genomics, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Agilent Technologies, Inc.Cash and cash equivalents up 34.6%
- Waters CorporationCash and cash equivalents up 80.7%
- Illumina, Inc.Shareholders' equity up 14.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- Avantor, Inc.Cash and cash equivalents up 39.5%
- Bio-Rad Laboratories, Inc.Shareholders' equity up 13.5%